Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.

Palbociclib D8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 (IC50s of 11 and 16 nM, respectively).

Palbociclib-Succinic acid is a Palbociclib- derivative with a succinic acid linker. The carboxy group of Palbociclib-Succinic acid can be used to conjugate with other molecules such as peptides, proteins, or polymers. Palbociclib-Succinic acid is a useful

Palbociclib-propargyl, a PROTAC ligand targeting the protein CDK6, connects to the CRBN ligand through a PEG linker to form PROTAC CP-10. CP-10 exhibits a potent DC50 value of 2.1 nM against CDK6[1].

Palbociclib-SMCC is a Palbociclib derivative with a SMCC linker.

Palbociclib (PD 0332991) dihydrochloride is an orally active, selective inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM). Palbociclib dihydrochloride has anti-proliferative activity and cell cycle arrest in HR-positive and HER2-negative breast cancers, as well as in hepatocellular carcinoma studies.

N-Methyl Palbociclib is an impurity of the orally active selective CDK4 and CDK6 inhibitor Palbociclib (PD 0332991).

Palbociclib Isethionate (PD 0332991 isethionate) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib (PD 0332991) hydrochloride is a selective and potent inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM). Palbociclib hydrochloride has anti-proliferative effects on cancer cells and induces cell cycle arrest, and can be used in research on HR-positive and HER2-negative breast cancer, as well as hepatocellular carcinoma.

Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively. This compound demonstrates potent anti-proliferative effects and induces cell cycle arrest in cancer cells, applicable in research concerning HR-positive, HER2-negative breast cancer, and hepatocellular carcinoma [1] [3] [4].

N-Formyl Palbociclib-d8 is a deuterated compound of N-Formyl Palbociclib. N-Formyl Palbociclib has a CAS number of 2174002-16-3.

6-Desacetyl Palbociclib is a useful organic compound for research related to life sciences and the catalog number is T64486.

Verapamil (CP-16533-1) is a calcium channel blocker and an orally active and effective inhibitor of P-gp. Verapamil inhibits CYP3A4 and can be used in studies about the treatment of high blood pressure, heart arrhythmias, and angina research.

Verapamil hydrochloride (Verapamil HCl) is a calcium channel blocker that is a class IV anti-arrhythmia agent.

BSJ-03-204 triTFA is a potent and selective Cereblon- and CDK-targeted PROTAC (PROteolysis TArgeting Chimera) featuring Palbociclib-based ligands for the degradation of CDK4/6. It exhibits IC50 values of 26.9 nM for CDK4/D1 and 10.4 nM for CDK6/D1, indicating strong inhibitory capabilities. Notably, it spares IKZF1/3 from degradation and possesses anti-cancer activity [1].

MSC2504877 is an inhibitor of tankyrase and enhances the effects of clinical CDK4/6 inhibitors. MSC2504877 suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib and enhances the suppression of phospho-Rb.